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Abstract 46 
Chronic kidney disease (CKD) research is limited by the lack of convenient inducible 47 
models mimicking human CKD and its complications in experimental animals. We demonstrate 48 
that a soluble oxalate-rich diet induces stable stages of CKD in male and female C57BL/6 mice. 49 
Renal histology is characterized by tubular damage, remnant atubular glomeruli, interstitial 50 
inflammation, and fibrosis with the extent of tissue involvement depending on the duration of 51 
oxalate feeding. Expression profiling of markers and magnetic resonance imaging findings 52 
established to reflect inflammation and fibrosis parallel the histological changes. Within 3 weeks 53 
the mice reproducibly develop normochromic anemia, metabolic acidosis, hyperkalemia, FGF23 54 
activation, hyperphosphatemia and hyperparathyroidism. In addition, the model is 55 
characterized by profound arterial hypertension as well as cardiac fibrosis that persist following 56 
the switch to a control diet. Together, this new model of inducible CKD overcomes a number of 57 
previous experimental limitations and should serve useful in research related to CKD and its 58 
complications. 59 
  60 
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Introduction 63 
Translational research in the area of chronic kidney disease (CKD) requires experimental 64 
models that (1) can be induced in C57BL/6 mice as it represents the most commonly used 65 
genetic background for gene manipulations, (2) reliably generate stable CKD, (3) result in CKD 66 
within a relatively short time to limit the burden for animals and reduce housing costs, (4) do 67 
not require surgery in order to minimize animal distress and the use of anesthetic drugs or pain 68 
killers with potentially confounding effects. In addition, an ideal model should (5) work in male 69 
and female mice with low inter-individual variability to allow sex-based comparisons in response 70 
to interventions and minimize animal use, (6) not reduce renal mass, which limits the tissue 71 
available for analysis, (7) reduce glomerular filtration rate (GFR) by more than 50% in order to 72 
allow detection of the changes in the clinical biomarkers plasma blood urea nitrogen (BUN) and 73 
creatinine, and (8) be associated with typical complications associated with CKD in humans, 74 
such as normochromic anemia, hyperphosphatemia, hyperparathyroidism, hyperkalemia, 75 
acidosis, hypertension, and cardiovascular disease. The present work reviews the most 76 
commonly used murine models of inducible CKD (1, 3, 12, 16) and contrasts them with a novel 77 
oxalate-induced model of stable CKD. 78 
 79 
Methods 80 
Animal studies and analytical methods 81 
Male and female 8-12 week old gender-matched C57BL/6 mice were obtained from 82 
Charles River Laboratories (Sulzfeld, Germany), housed in groups of five mice in standard 83 
housing conditions with unlimited access to food and water. Oxalate diet was prepared by 84 
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adding 50 μmol/g sodium oxalate to a calcium-free standard diet (Ssniff, Soest, Germany) as 85 
previously described (15). Removal of calcium from the diet increases the amount of soluble 86 
oxalate available for absorption as previously shown (15). Oxalate- and calcium-free diet 87 
(control diet) was given for 3 days to eliminate any residual intestinal calcium before switching 88 
to high soluble oxalate diet and used after ending the oxalate feeding period. All experimental 89 
procedures were approved by the local government authorities. 90 
 91 
Assessment of renal injury 92 
Mice kidney sections of 2 μm were stained with periodic acid-Schiff (PAS) reagent. Tubular 93 
injury was scored by assessing the percentage of necrotic tubules and presence of tubular casts. 94 
F4/80+ve positive macrophages, CD3+ve T cells (both Serotec, Oxford, UK) were identified by 95 
immunostaining and were counted in 15 high power fields (hpf) per section using Image J 96 
software. Similar approach was also used to quantify Silver stains. Fibrotic areas were identified 97 
by Silver stain, Masson Trichrome stain & Collagen 1a1 and were quantified using Image J 98 
software. Serial sections of the kidney were stained with Tetragonolobus lectin to observe 99 
atubular glomeruli. All assessments were performed by an observer blinded to the experimental 100 
condition. 101 
 102 
RNA preparation and real-time quantitative -PCR 103 
Total RNA was isolated from kidneys using a Qiagen RNA extraction kit (Qiagen, Germany) 104 
following the manufacturer’s instructions. After quantification RNA quality was assessed using 105 
agarose gels. From isolated RNA, cDNA was prepared using reverse transcriptase (Superscript II) 106 
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(Invitrogen, USA). Real time RT-PCR was performed using SYBRGreen PCR master mix and was 107 
analyzed with a Light Cycler 480 (Roche, Germany). All gene expression values were normalized 108 
using 18s RNA as a house keeping gene. All primers used for amplification were from Metabion 109 
(Martinsried, Germany) and are listed in Table 1. 110 
 111 
Hematological analysis 112 
Hematological analysis was performed using prefilled Sysmex capillary tubes (Sysmex 113 
Deutschland GmbH, Norderstedt, Germany). An aliquot of 50µl EDTA-blood was determined by 114 
using a 50µl end-to-end capillary and was diluted 1:5 in 200µl prefilled Sysmex Cellpack buffer. 115 
Diluted samples were stored at room temperature until analysis. Complete peripheral blood 116 
counts, differential leukocyte counts and reticulocyte counts were determined with a Sysmex 117 
XT2000iV hematology analyzer (Sysmex Deutschland GmbH, Norderstedt, Germany) in the 118 
“capillary blood” mode using the option “CBC DIFF RET” as described previously (23) with the 119 
following parameters included: 120 
Total white blood cell count (WBC), total red blood cell count (RBC), platelet count (PLT), 121 
hemoglobin concentration (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean 122 
corpuscular hemoglobin content (MCH), mean corpuscular hemoglobin concentration (MCHC), 123 
red cell distribution width – coefficient of variance (RDW-CV), mean platelet volume (MPV), 124 
platelet distribution width (PDW), platelet large cell ratio (P-LCR), plateletcrit (PCT), absolute cell 125 
counts and proportions of WBC for lymphocytes (LYMPH), monocytes (MONO)  as well as  126 
neutrophil (NEUT), eosinophil (EO) and basophil (BASO) granulocytes, and absolute cell counts 127 
and proportion of RDW of reticulocytes (RET), including proportions of reticulocyte maturation 128 
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states as determined by fluorescence intensity, mature low fluorescent reticulocytes (LFR), less 129 
mature medium fluorescent reticulocytes (MFR) and very immature highly fluorescent 130 
reticulocytes (HFR), as well as the sum of MFR and HFR as immature reticulocyte fraction (IRF). 131 
 132 
Clinical chemistry analyses 133 
Inorganic phosphate (Pi) was analyzed using an AU480 Clinical chemistry analyzer (Beckman-134 
Coulter GmbH, Krefeld, Germany) and adapted test kits provided by Beckman Coulter in either 135 
undiluted or 1:2 with deionized water diluted EDTA-treated plasma samples as described 136 
previously (24). Heparinized capillaries were filled with 100 µL of whole blood and subjected to 137 
measurement of potassium and pH using a blood gas analyzer (ABL 835 Flex, Radiometer GmbH, 138 
Willich, Germany). 139 
  140 
Blood pressure measurements 141 
Blood pressure was measured continuously in male 10-12 week old C57BL/6 mice using an intra-142 
arterial telemetric transmitter system as previously described (3). In brief, under isoflurane 143 
anesthesia a transmitter device (PhysioTel™ TA11PA-C10; Data Sciences International DSI, St. 144 
Paul, Minnesota, USA) was surgically implanted into the left common carotid artery one week 145 
prior to data sampling. The transmitter was placed subcutaneously over the abdominal area. All 146 
animals were then housed in open cages and allowed to recover for two weeks during which 147 
mice received unlimited access to regular chow (Ssniff, Soest, Germany) and tap water. 148 
Following recovery, the diet was changed to synthetic calcium-and oxalate-free diet (0% Ca 0% 149 
Oxalate, TD. 95027, Ssniff) for one week, followed by high oxalate diet (0% Ca 0.67% Oxalate, 150 
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TD. 95027, Ssniff) for 8 days and thereafter control diet for another 10 days. Blood pressure was 151 
detected and recorded continuously for 5 weeks by the Dataquest A.R.T. System (Data Sciences 152 
International DSI, St. Paul, Minnesota, USA). Systolic and diastolic blood pressure values were 153 
calculated as average of the last 24h-day of each diet period by the Dataquest ART 4.1 software 154 
(DSI). Mean arterial pressure (MAP) was calculated from diastolic and systolic pressure values 155 
using a standard equation. 156 
 157 
Transcutaneous measurement of glomerular filtration rate (GFR) in conscious mice 158 
For GFR measurement mice where anesthetized with isoflurane and a miniaturized imager 159 
device built from two light-emitting diodes, a photodiode and a battery (Mannheim Pharma & 160 
Diagnostics GmbH, Germany) was mounted via a double-sided adhesive tape onto the shaved 161 
animal’s neck (26). For the duration of recording (approx. 1.5 h) each animal was conscious and 162 
kept in a single cage. Prior to the intravenous injection of 150 mg/kg FITC-sinistrin (Mannheim 163 
Pharma & Diagnostics GmbH, Germany), the skin's background signal was recorded for 5 min. 164 
After removing the imager device the data were analyzed using MPD Lab software (Mannheim 165 
Pharma & Diagnostics GmbH, Germany). The GFR [µl/min] was calculated from the decrease of 166 
fluorescence intensity over time (i.e. plasma half-life of FITC-sinistrin) using a two-compartment 167 
model, body weight of mouse and an empirical conversion factor (26). 168 
 169 
Measurement of intact FGF23, PTH and phosphorus 170 
The plasma concentration of intact FGF23 (Kainos Laboratories, Japan or Immutopics 171 
International, USA) and intact PTH (Immutopics International, USA) were measured by enzyme-172 
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linked immunosorbent assays according to the manufacturers protocols. Phosphate was 173 
measured by the phosphomolybdate method (9, 10). 174 
 175 
Magnetic resonance imaging (MRI) 176 
Excised kidneys (n=12) from C57BL/6 male mice fed either high oxalate (n=6 kidneys) or control 177 
diet (n=6 kidneys) for 21 days were processed in 2% agarose and placed in a whole body coil for 178 
mice (Bruker, Ettlingen, Germany) of a dedicated small animal ultra-high-field MR scanner 179 
(ClinScan 7 Tesla, Bruker, Ettlingen, Germany). Standard sequences for morphology and 180 
mapping of T1-, T2- and T2*- relaxation times as well as of the apparent diffusion coefficient 181 
(ADC) (Siemens, Erlangen, Germany) were performed on kidneys in sagittal orientation 182 
(compare Fig. 5). By mapping of relaxation times, specific magnetic properties of tissues are 183 
quantified, which can be performed in multiple tissues and organs. Thereby an increase of T1 184 
relaxation time may be associated with fibrosis, while prolonged T2 relaxation times are found 185 
in inflammation (25). Furthermore, calculation of the ADC by diffusion-weighted imaging 186 
captures the Brownian motion of water molecules that is locally altered in pathologic conditions 187 
like fibrosis, resulting in decreased water diffusion, and thus decreased ADC values (11). For 188 
post-processing of images, 3 regions of interest were placed in the cortex, medulla and 189 
transitional zone, respectively, to determine T1-, T2- and T2*- relaxation times as well as the 190 
ADC (Osirix, open-source software). Furthermore, the volume of the cortex was determined on 191 
morphological, T2 weighted images (Osirix, open-source software). 192 
 193 
Histological examination of cardiac fibrosis 194 
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Hearts were excised, snap frozen in liquid nitrogen and stored at -80 °C until further use. The 195 
lower base of the left ventricle was embedded in tissue tec, whereupon 10 µm thick cross-196 
sections were prepared on a SLEE-MNT cryostat (Mainz, Germany). Ventricular sections were 197 
stained for fibrotic tissue using Masson’s trichrome staining (Sigma-Aldrich, Taufkirchen, 198 
Germany). Briefly, sections were fixed in 4% paraformaldehyde for 1 h at room temperature and 199 
refixed overnight in Bouin’s solution. The next day, slides were washed in distilled water and 200 
incubated for 5 min with hematoxylin. After washing the slides in distilled water for 10 min, 201 
sections were incubated for 5 min in biebrich scarlet acid fuchsin. Slides were washed 3 times in 202 
distilled water, where after they were incubated in phosphomolybdic acid 3 times each for 3 203 
min. After 5 min of incubation with aniline blue, which leads to a blue staining of fibrotic tissue, 204 
slides were rinsed in distilled water and dehydrated in isopropanol and xylene, before they were 205 
mounted with roti-histokit (Carl Roth, Karlsruhe, Germany). Differentiation was performed by 206 
incubating the slides 2 min in ice-cold acetic acid. After a washing step in distilled water, slides 207 
were covered with mounting medium. Microscopic composite images of the complete cross-208 
sections were obtained at x150 magnification on a light microscope (Olympus IX70, Hamburg, 209 
Germany) with an inverted CCD-camera (Nikon DXM1200, Düsseldorf, Germany). Blue-stained 210 
fibrotic area was manually quantified by an observer blinded to the experimental condition on 211 
three cross-sections per heart using Image J software. The endocardium and trabeculae carnae 212 
were excluded from quantification. After determination of the ventricular area, the mean 213 
fibrosis content was calculated by dividing the area of Trichrome-stained fibrotic fibers by total 214 
left ventricular area. For qualitative electron microscopic investigations of the hearts several 215 
semithin and ultrathin sections were prepared and stained with methylene blue or uranyl 216 
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acetate/lead citrate, respectively. Images of ultrathin sections were taken with a Zeiss electron 217 
microscope LEO EM 910 (Zeiss, Oberkochen, Germany). 218 
 219 
Preparation of femoral bones 220 
Femoral bones were removed, weighed and fixed overnight using 1% (w/v) PFA buffered with 221 
PBS pH 7.4. Bones were decalcified in 10% (w/v) EDTA solution pH 7.4 before they were 222 
dehydrated and embedded in paraffin. Tissues were cut into 2-μm sections and stained with 223 
hematoxylin and eosin (H & E). Images were taken using BX60 Olympus microscope equipped 224 
with a XC 30 camera (Olympus BC, Hamburg, Germany). 225 
 226 
Results 227 
A diet high in soluble oxalate induces stable CKD 228 
Previous work from our groups suggests that intraperitoneal oxalate can induce acute 229 
kidney injury (22), and a high oxalate diet can cause progressive renal failure (15). In the present 230 
study we first examined the effects of duration of feeding a soluble oxalate diet on renal 231 
function in C57BL/6 mice. Providing an oxalate diet induced a decline in GFR and an increase in 232 
plasma BUN and creatinine (Fig. 1A-C). Shorter duration of oxalate feeding followed by 233 
switching to control diet induced less advanced stages of CKD as defined by GFR, plasma BUN 234 
and creatinine (Fig. 1D-F). Serial monitoring documented that these parameters peaked at the 235 
end of oxalate feeding followed by mild recovery over the following 2 week period. Urinary 236 
oxalate increased following a switch to a soluble oxalate as compared to control diet (Fig. 1G) 237 
but no renal or bladder stones were detected (images not shown). Similarly, we observed a 238 
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sharp increase in plasma oxalate levels followed by a reduction of plasma oxalate levels when 239 
mice were switched back to control diet (Fig. 1H). Therefore, while a diet high in soluble oxalate 240 
was found to induce a progressive decline in renal function as previously reported (13), these 241 
results show for the first time that it can also be used to induce stable CKD after dietary oxalate 242 
is discontinued. 243 
 244 
Renal pathology of oxalate-induced CKD 245 
As progressive scarring and fibrotic processes are a hallmark of CKD irrespective of the 246 
initiating disease, we next examined renal histology of mice fed a soluble oxalate diet for 247 
various durations. Periodic acid-Schiff (PAS) staining revealed progressive tubular atrophy (Fig. 248 
2A) resulting in remnant atubular glomeruli (Fig. 2B) (2, 17). In addition, infiltration by 249 
macrophages/monocytes and T cells was observed, mainly in areas of interstitial fibrosis (Fig. 250 
3A). Furthermore, progressive renal fibrosis was demonstrated as measured by Collagen I, Silver 251 
and Trichrome staining, and the duration of feeding allowed titration of the degree of 252 
parenchymal loss (Fig. 3A). Expression profiling for markers of kidney injury, inflammation and 253 
fibrosis were consistent with progressive kidney atrophy (Fig. 3B). Female C57BL/6 mice 254 
revealed similar findings with very low inter-individual variability (Fig. 4A-F). Given the 255 
increasing use of diagnostic imaging modalities to assess changes of renal morphology, we 256 
performed magnetic resonance imaging (MRI) of kidneys from mice. As compared to mice 257 
receiving a control diet, animals receiving an oxalate diet displayed an increase in kidney cortex 258 
volume, T1-, T2- and T2*- relaxation times as well as a reduction of the apparent diffusion 259 
coefficient in the cortex (Fig 5). These significant differences in the cortex are known to be 260 
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associated with inflammation (increased volume and T2-time) and fibrosis (increased T1-time 261 
and decreased diffusion), and are consistent with findings from histology and expression 262 
profiling (25). Taken together, these data indicate that a high oxalate diet induces CKD in male 263 
and female C57BL/6 mice characterized by progressive kidney atrophy and fibrosis. 264 
 265 
Oxalate-induced CKD in C57BL/6 mice demonstrates classical CKD complications 266 
We next examined whether the mouse model displays human CKD complications. 267 
Oxalate diet induced normochromic anemia (Fig. 6A) without affecting other blood cell lines 268 
(Supplementary Table 1). CKD-related mineral bone disease (CKD-MBD) was demonstrated by 269 
elevated plasma FGF23 and PTH levels as well as hyperphosphatemia and hyperkalemia (Fig. 6B-270 
E) in addition to metabolic acidosis (Fig. 6F). Bone marrow of femoral bones demonstrated no 271 
oxalate crystal deposition of mice receiving an oxalate diet (Fig. 6G). Furthermore, oxalate diet 272 
induced arterial hypertension (Fig. 7A and B), which persisted after cessation of the oxalate-rich 273 
diet (Fig. 7C and D). In addition, oxalate feeding induced cardiac fibrosis (Fig. 7E and F), another 274 
serious cardiovascular complication of CKD. Electron microscopy demonstrated fibroblast 275 
activation in mice receiving an oxalate diet, as demonstrated by an increase in size and 276 
vacuolization of fibroblasts as compared with mice receiving a control diet (Fig. 7G; white 277 
arrows). Similar to our observation in femoral bones, we could not detect any oxalate crystal 278 
deposition in heart tissue arguing against systemic oxalosis to explain the observed phenotype.  279 
Thus, this model of oxalate diet-induced CKD presents with a wide spectrum of clinically 280 
established CKD complications. 281 
 282 
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It is of interest to compare the features of this oxalate-induced model of CKD with 283 
previous models of CKD, as summarized in Table 2. 284 
 285 
Discussion 286 
The model of unilateral ureteral obstruction (UUO) has become a widely used model to 287 
study CKD and fibrosis (3). While the model causes extensive parenchymal damage, functional 288 
compensation by the intact contralateral kidney prevents a significant change of renal function 289 
and the development of CKD complications (29). Absence of urine from the damaged kidney 290 
precludes biomarker discovery studies. In contrast, the oxalate-diet induced CKD model enables 291 
study of renal fibrosis while providing a functional endpoint of renal function as changes in GFR, 292 
serum BUN and creatinine can be measured. It also allows the collection of urine and 293 
demonstrates established CKD complications. 294 
The renal mass reduction models have been a mainstay of CKD studies (16). Unilateral 295 
nephrectomy is followed by either partial infarction or amputation of the poles of the remaining 296 
kidney resulting in glomerular and tubule-interstitial injury. A strong limitation of the model is 297 
the need for two surgical interventions requiring microsurgery training, confounding effects 298 
related to anesthesia as well as surgical procedures, and the model’s reproducibility and 299 
variability (16). In addition, performing 5/6 nephrectomy limits the tissue available for analysis. 300 
After 16 weeks, the C57BL/6 mice demonstrate increased albuminuria without increased blood 301 
pressure and without developing cardiac fibrosis unless angiotensin II is administered (18). The 302 
oxalate diet induced-model requires no microsurgery training/intervention, maintains sufficient 303 
renal tissue for analysis, and reliably induces CKD complications. 304 
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The adenine-induced model of CKD - unlike UUO or renal mass reduction – does not 305 
require surgery. It has largely been established in rats (32) as it is not easily adapted to mice 306 
given their reluctance to consume adenine. Addition of casein appears to blunt the smell and 307 
taste of adenine in order to apply the approach to mice (13). Male mice present a more severe 308 
renal phenotype as compared with female mice presumably secondary to gender differences in 309 
the metabolism of adenine (7, 27). In addition, the model requires diets of different adenine 310 
content (13) or induction for 6 weeks (28). Most strikingly, the mice develop profound 311 
hypotension compared with mice receiving a control diet (19) In contrast, oxalate is readily 312 
eaten by mice; the amount of dietary intake can be precisely monitored by measuring urinary 313 
oxalate excretion. Additional benefits include the short time frame of 1-3 weeks for the 314 
induction of moderate to advanced CKD, which accelerates scientific work flow and reduces 315 
housing costs. Most strikingly, the oxalate model induces reliable and profound hypertension, 316 
an established complication of CKD in humans. 317 
 The aristolochic acid model represents an additional tool to investigate mechanisms of 318 
CKD progression and to access potential interventions (6, 12). Aristolochic acid I (AAI) is the 319 
active ingredient implicated in Chinese herb nephropathy. Intraperitoneal injection of AAI 320 
weekly has been shown to lead to progressive fibrosis and kidney failure that is more severe in 321 
male than female mice (6, 12), similar to observations made in the adenine model. No 322 
significant hypertension ensues (12). Contrary to the AAI model, the oxalate diet-induced model 323 
avoids direct handling and injections of mice. As the oxalate model works in male and female 324 
mice, it allows examination of gender differences in response to pharmaceutical interventions 325 
to treat CKD, providing a platform to use both male and female mice in preclinical studies as 326 
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requested by the National Institute of Health (4). In addition, gender-restricted models produce 327 
excess pups, which are avoided when both males and females can be used for experimentation, 328 
and the low inter-individual variability allows smaller group sizes.  329 
 The folic acid nephropathy model induces interstitial fibrosis following i.p. injection of 330 
high dosage of folic acid. The advantage of the model as compared with the UUO model is that 331 
renal function can be assessed. However, the model requires i.p. injections as compared with 332 
the oxalate feeding model, is somewhat variable and yet to be characterized in regards to 333 
gender differences and CKD complications (8, 30, 31). 334 
 335 
Despite these advantages of the oxalate model over previous CKD models, a number of 336 
limitations have to be considered. Oxalate crystals primarily induce tubular injury (20-22), while 337 
many forms of human CKD are primarily driven by podocyte loss (5). The mechanism of crystal-338 
induced progression may not translate to all forms of CKD. However, the extensively studied 339 
adenine and folic acid model are similarly crystal-induced (19). Likewise, one may argue that 340 
UUO as the benchmark model of fibrosis associated with an increase of vascular resistance and 341 
a reduced blood flow following surgery provides a mechanism of fibrosis not mimicking the 342 
pathophysiology of common forms of CKD (14). 343 
Nevertheless, several elements of the oxalate model including tubular atrophy, renal 344 
inflammation, and fibrosis are common to many forms of CKD. In addition, one of the major 345 
strengths of the model is the reproducibility of CKD complications thereby allowing study of the 346 
mechanisms of FGF23 activation, hyperphosphatemia, hyperparathyroidism, hypertension and 347 
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cardiac fibrosis. Moreover, increasing the number of CKD models available may help to validate 348 
important findings and improve standards. 349 
In conclusion, feeding a soluble oxalate diet represents a simple, reproducible and 350 
technically undemanding CKD model providing functional data in male as well as female 351 
C57BL/6 mice. Moreover, the duration of feeding enables titrated induction of various stages of 352 
CKD associated with numerous clinically important CKD complications. Thus, the oxalate diet-353 
induced CKD model offers novel opportunities for CKD research. 354 
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Figure legends 460 
Figure 1. A diet high in soluble oxalate induces progressive or stable CKD. A-C: C57BL/6 male 461 
mice were fed either high oxalate or control diet for 21 days and (A) GFR, (B) plasma BUN, and 462 
(C) plasma creatinine were measured at baseline, days 7, 14 and 21. D-F: C57BL/6 male mice 463 
received high oxalate diet for 0, 7 or 14 days respectively and thereafter control diet for 14 464 
days. (D) GFR, (E) plasma BUN, (F) plasma creatinine, (G) urine oxalate and (H) plasma oxalate 465 
were measured at indicated time points. Data are mean ± SEM from 5 mice in each group. 466 
*p<0.05, **p<0.01 and ***p<0.001 versus control group. 467 
 468 
Figure 2. Oxalate-induced CKD shows atubular glomeruli. C57BL/6 male mice were fed either 469 
high oxalate or control diet for 21 days. (A) PAS staining at various time points and 470 
quantification, (B) Serial sections of the kidney were stained with Tetragonolobus lectin to 471 
observe atubular glomeruli. Note the atubular glomerulus (clearly separated by a membrane) is 472 
surrounded by tubules containing crystals. Data are mean ± SEM from 7-8 mice in each group. 473 
**p<0.01 and ***p<0.001 versus control group. 474 
 475 
Figure 3. Pathology of oxalate-induced CKD in male mice. C57BL/6 male mice were fed either 476 
high oxalate or control diet for 21 days. (A) F4/80, CD3, Collagen I, Silver, Masson Trichrome 477 
staining and their quantification, (B) Gene expression of kidney injury (TIMP-2, Kim-1), 478 
inflammation (RANTES, TNFα, IL-6) and fibrosis (Fibronectin, FSP-1, Col1a1) was analyzed using 479 
RT-PCR at different time points. Data are mean ± SEM from 7-8 mice in each group. *p<0.05, 480 
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**p<0.01 and ***p<0.001 versus control group. +p<0.05, ++p<0.01 and +++p<0.001 versus control 481 
group. ##p<0.01 and ###p<0.001 versus control group. 482 
 483 
Figure 4. Oxalate-induced CKD in female mice. C57BL/6 female mice were fed either high 484 
oxalate or control diet for 21 days. Note that female mice develop comparable CKD to male 485 
mice. (A) Plasma BUN levels. (B) Plasma creatinine levels. (C) Quantification of tubular injury. (D) 486 
Quantification of CD3+ve cells. (E) Quantification of CaOx crystal deposits, F4/80+ve 487 
macrophages, Masson Trichrome, Silver and Collagen I+ve area. (F) mRNA expression of kidney 488 
injury markers, pro-inflammatory genes and pro-fibrotic genes. Data are mean ± SEM from 7-8 489 
mice in each group. *p<0.05, **p<0.01 and ***p<0.001 versus control group. 490 
 491 
Figure 5. Magnetic resonance imaging (MRI) of oxalate-induced CKD. MRI was performed on 492 
kidneys of C57BL/6 male mice fed either high oxalate or control diet for 21 days. (A, B) On 493 
representative morphological images, contrast characteristics of kidneys in the cortex, medulla 494 
and transitional zone could be visualized. (C) Quantitative parameters on total cortex volume, 495 
(D) T1 - relaxation time, (E) T2 - relaxation time, (F) T2* - relaxation time and (G) Apparent 496 
diffusion coefficient (ADC) showed significant differences between the groups in cortex, medulla 497 
or transitional zone. C, cortex; M, medulla; CM, transitional zone.  Data are mean ± SEM from 7-498 
8 mice in each group. *p<0.05, **p<0.01 and ***p<0.001 versus control group. 499 
 500 
Figure 6. Oxalate-induced CKD demonstrates classical CKD complications. A-F: C57BL/6 male 501 
mice were fed either high oxalate or control diet for 21 days and different parameters for CKD 502 
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complications were analyzed.  (A) Hemoglobin levels in blood. (B) Plasma FGF-23 levels. (C) 503 
Plasma parathyroid hormone levels. (D) Plasma phosphorous levels. (E) Plasma potassium levels 504 
(F). pH of blood. (G) HE staining of femoral bones. Data are mean ± SEM from 4-5 mice in each 505 
group. *p<0.05, **p<0.01 and ***p<0.001 versus control group. 506 
 507 
Figure 7. Oxalate-induced CKD demonstrates hypertension and cardiac fibrosis. (A) Mean 508 
arterial blood pressure. (B) Heart Rate. C-D: C57Bl6 male mice received high oxalate diet for 8 509 
days and thereafter control diet for 10 days. (C) Mean arterial blood pressure. (D) Heart Rate. E-510 
F: Cardiac fibrosis was quantified (E) on Masson trichrome staining of heart cross-sections (F) at 511 
day 21 after high oxalate diet. (G) Electron microscopy of heart sections. Data are mean ± SEM 512 
from 4-5 mice in each group except for n=2 at day 18 (control diet fed group) in C-D. *p<0.05, 513 
**p<0.01 and ***p<0.001 versus control group. 514 
515 
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Table 1. Primers sequences 517 
Target                                            Primer sequence
KIM1 Forward   5’-TCAGCTCGGGAATGCACAA -3’
Reverse   5’-TGGTTGCCTTCCGTGTCTCT  -3’ 
TIMP2 Forward            5`-CAGACGTAGTGATCAGAGCCAAA -3` 
Reverse             5`-ACTCGATGTCTTTGTCAGGTCC -3` 
RANTES  Forward 5’- GTGCCCACGTCAAGGAGTAT-3’
Reverse   5’- CCACTTCTTCTCTGGGTTGG-3’ 
IL 6 
 
Fibronectin 
Forward   5’- TGATGCACTTGCAGAAAACA -3’    
Reverse   5’- ACCAGAGGAAATTTTCAATAGGC - 3’ 
Forward  5’-GGAGTGGCACTGTCAACCTC  - 3’ 
 
Collagen1a1 
Reverse 5’-ACTGGATGGGGTGGGAAT - 3’
Forward  5’-ACATGTTCAGCTTTGTGGACC -3’  
Reverse   5’-TAGGCCATTGTGTATGCAGC- 3’ 
FSP-1 Forward 5’- CAGCACTTCCTCTCTCTTGG -3’ 
Reverse  5’-TTTGTGGAAGGTGGACACAA - 3’ 
TNF-alpha Forward 5’- CCACCACGCTCTTCTGTCTAC  -3’ 
Reverse  5’-AGGGTCTGGGCCATAGAACT - 3’ 
Alpha-SMA 
 
Forward 5’- ACTGGGACGACATGGAAAAG-3’ 
Reverse  5’- GTTCAGTGGTGCCTCTGTCA- 3’ 
iNOS Forward 5’- GAGACAGGGAAGTCTGAAGCAC-3’ 
 Reverse 5’- CCAGCAGTAGTTGCTCCTCTTC-3’
18s RNA Forward 5’- GCAATTATTCCCCATGAACG-3’ 
Reverse  5’- AGGGCCTCACTAAACCATCC- 3’ 
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Table 2: Comparison of murine CKD models. 518 
 
CKD Animal Models 1 2 3 4 5 6 7 8 References 
Unilateral ureteral obstruction 
(UUO) 
   -  - - - (3, 29) 
Surgical renal mass ablation 
(5/6 Nephrectomy) 
  - -  - -  (16, 18) 
Adenine-induced CKD   -  -   - (7, 13, 19, 
27, 28, 32) 
Aristolochic acid-induced CKD     -   - (6, 12) 
Folic acid-induced CKD  - -  ?   ? (8, 30, 31) 
Oxalate-induced CKD          
 519 
Criteria 520 
1. Inducible in C57BL/6 mice 521 
2. Reliable induction of stable CKD 522 
3. Require relatively short time to induce CKD and, thus, limit the burden for animals, reduce 523 
housing costs 524 
4. Avoid surgical interventions, thus, minimize animal distress and use of painkillers 525 
5. Inducible in male and female mice with low inter-individual variability 526 
6. Avoid reduction in renal mass 527 
7. Reduction in GFR 528 
8. CKD complications such as normochromic anemia, hyperphosphatemia, 529 
hyperparathyroidism, hyperkalemia, acidosis, hypertension, and cardiovascular disease. 530 
 531 







